title: Drug-printing by flexographic printing technology--a new manufacturing process for orodispersible films.
abstract: Orodispersible films (ODFs) are intended to disintegrate within seconds when placed onto the tongue. The common way of manufacturing is the solvent casting method. Flexographic printing on drug-free ODFs is introduced as a highly flexible and cost-effective alternative manufacturing method in this study. Rasagiline mesylate and tadalafil were used as model drugs. Printing of rasagiline solutions and tadalafil suspensions was feasible. Up to four printing cycles were performed. The possibility to employ several printing cycles enables a continuous, highly flexible manufacturing process, for example for individualised medicine. The obtained ODFs were characterised regarding their mechanical properties, their disintegration time, API crystallinity and homogeneity. Rasagiline mesylate did not recrystallise after the printing process. Relevant film properties were not affected by printing. Results were comparable to the results of ODFs manufactured with the common solvent casting technique, but the APIs are less stressed through mixing, solvent evaporation and heat. Further, loss of material due to cutting jumbo and daughter rolls can be reduced. Therefore, a versatile new manufacturing technology particularly for processing high-potent low-dose or heat sensitive drugs is introduced in this study.
authors.affiliation: Institute of Pharmaceutics and Biopharmaceutics, Heinrich-Heine-University, Universitätsstr. 1, 40225 Düsseldorf, Germany. e.m.hoffmann@uni-duesseldorf.de
authors.forename: Eva Maria
authors.initials: EM
authors.lastname: Janssen
authors.forename: Ralf
authors.initials: R
authors.lastname: Schliephacke
authors.forename: Armin
authors.initials: A
authors.lastname: Breitenbach
authors.forename: Jörg
authors.initials: J
authors.lastname: Breitkreutz
mesh_terms: D002243:Carbolines / Q000008:administration & dosage* / Q000737:chemistry; D003362:Cost-Benefit Analysis; D003460:Crystallization; D004339:Drug Compounding / Q000191:economics / Q000379:methods*; D016503:Drug Delivery Systems; D004355:Drug Stability; D005240:Feasibility Studies; D007189:Indans / Q000008:administration & dosage* / Q000737:chemistry; D012997:Solvents / Q000737:chemistry; D000068581:Tadalafil; D013678:Technology, Pharmaceutical / Q000191:economics / Q000379:methods; D013997:Time Factors
chemical_list: D002243:Carbolines; D007189:Indans; D012997:Solvents; C031967:rasagiline; D000068581:Tadalafil